Published in Drug Metab Pharmacokinet on January 01, 2009
Population-based mechanistic prediction of oral drug absorption. AAPS J (2009) 1.38
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol (2013) 1.27
What is the right dose for children? Br J Clin Pharmacol (2010) 1.24
The simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol (2013) 1.11
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol (2015) 1.06
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol (2009) 1.02
A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol (2012) 1.02
Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. Curr Pharmacol Rep (2016) 0.98
Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet (2014) 0.98
Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos (2015) 0.97
Dose selection based on physiologically based pharmacokinetic (PBPK) approaches. AAPS J (2012) 0.96
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos (2013) 0.91
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol (2014) 0.91
Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol (2014) 0.90
Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol (2012) 0.87
Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J (2011) 0.85
Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs. CPT Pharmacometrics Syst Pharmacol (2015) 0.84
Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. CPT Pharmacometrics Syst Pharmacol (2014) 0.83
Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling. CPT Pharmacometrics Syst Pharmacol (2012) 0.83
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
FutureTox: building the road for 21st century toxicology and risk assessment practices. Toxicol Sci (2013) 0.81
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacometrics Syst Pharmacol (2016) 0.80
Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. CPT Pharmacometrics Syst Pharmacol (2014) 0.80
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos (2013) 0.80
Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metab Dispos (2016) 0.79
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J (2014) 0.79
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clin Pharmacokinet (2016) 0.79
MEGen: A Physiologically Based Pharmacokinetic Model Generator. Front Pharmacol (2011) 0.79
Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. PLoS One (2015) 0.78
Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol (2016) 0.78
Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol (2013) 0.77
Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med (2015) 0.76
Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy. Proc Natl Acad Sci U S A (2017) 0.75
Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System. J Pharmacol Exp Ther (2016) 0.75
Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation Approach. J Toxicol (2012) 0.75
Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. AAPS J (2014) 0.75
Evaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of Chemicals. Front Pharmacol (2016) 0.75
Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety? Sci Rep (2016) 0.75
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and Simulations. Curr Pharmacol Rep (2016) 0.75
A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE. Front Pharmacol (2015) 0.75
Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques. Pharm Res (2015) 0.75
Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. J Clin Pharmacol (2016) 0.75
Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach. AAPS J (2013) 0.75
Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacol Sin (2015) 0.75
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. Pharmacol Res Perspect (2017) 0.75
Humans Vary, So Cardiac Models Should Account for That Too! Front Physiol (2017) 0.75
The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol (2009) 1.88
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet (2006) 1.69
Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab (2009) 1.57
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet (2011) 1.55
Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl (2005) 1.41
Population-based mechanistic prediction of oral drug absorption. AAPS J (2009) 1.38
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet (2012) 1.36
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet (2010) 1.34
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth (2011) 1.31
Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) (2004) 1.22
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab (2007) 1.22
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab (2008) 1.22
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer (2005) 1.16
Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. J Clin Pharmacol (2014) 1.12
Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clin Pharmacokinet (2015) 1.09
Prediction of intestinal first-pass drug metabolism. Curr Drug Metab (2007) 1.09
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol (2015) 1.06
Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol (2005) 1.03
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol (2006) 0.99
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2009) 0.98
Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol (2011) 0.97
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol (2012) 0.97
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol (2013) 0.95
Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther (2004) 0.94
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol (2008) 0.92
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol (2014) 0.91
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos (2013) 0.91
Pharmacometrics in pregnancy: An unmet need. Annu Rev Pharmacol Toxicol (2014) 0.91
Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharm Drug Dispos (2015) 0.89
Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab (2010) 0.89
Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol (2008) 0.89
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos (2011) 0.89
Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos (2007) 0.89
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol (2007) 0.88
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol (2011) 0.88
Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol (2013) 0.87
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol (2012) 0.86
The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci (2003) 0.86
Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos (2014) 0.85
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol (2004) 0.85
A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet (2014) 0.84
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol (2012) 0.84
Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci (2013) 0.83
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J Pharm Sci (2012) 0.83
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica (2011) 0.82
An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol (2002) 0.82
Fraction absorbed (Fabs ): different connotations and confusion for the literature? Biopharm Drug Dispos (2011) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci (2013) 0.81
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. J Pharmacokinet Pharmacodyn (2015) 0.81
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci (2006) 0.81
Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica (2007) 0.81
Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol (2003) 0.80
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol (2007) 0.80
Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil Steril (2006) 0.80
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharm Res (2014) 0.79
Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharm Drug Dispos (2014) 0.79
Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res (2003) 0.79
The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology (2002) 0.79
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos (2010) 0.79
Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol (2012) 0.79
Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res (2013) 0.79
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res (2013) 0.79
CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet (2008) 0.79
Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine. Pharm Res (2014) 0.79
Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. Drug Metab Dispos (2011) 0.79
Can saliva replace plasma for the monitoring of methadone? Ther Drug Monit (2005) 0.79
Do children have the same vulnerability to metabolic drug–drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol (2013) 0.79
Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab (2012) 0.78
The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy). J Psychopharmacol (2006) 0.78
Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques. Expert Opin Drug Metab Toxicol (2015) 0.77
Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. J Pharm Sci (2009) 0.77
Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol. Eur J Pharm Sci (2005) 0.76
Toxicokinetics and metabolism. Altern Lab Anim (2005) 0.76
Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm Drug Dispos (2011) 0.76
Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site. AAPS J (2015) 0.76
Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay! Biopharm Drug Dispos (2012) 0.76
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm Stat (2009) 0.76
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol (2013) 0.76
Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis. AAPS J (2015) 0.75
Predicting the clearance of CYP2C9 substrates. Drug Metab Dispos (2004) 0.75
Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles? J Assist Reprod Genet (2006) 0.75
Evaluation of the relationship between plasma concentrations of en- and zuclomiphene and induction of ovulation in anovulatory women being treated with clomiphene citrate. Fertil Steril (2008) 0.75
Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci (2007) 0.75
Kinetics of the time-dependent inactivation of CYP2D6 in cryopreserved human hepatocytes by methylenedioxymethamphetamine (MDMA). Eur J Pharm Sci (2007) 0.75
Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor expression in human lung. Pulm Pharmacol Ther (2009) 0.75
Erratum to: A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo Data. Clin Pharmacokinet (2015) 0.75
Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition. Eur J Pharm Sci (2007) 0.75
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used? J Clin Pharmacol (2013) 0.75